NO974561L - Chlamydia-vaksine - Google Patents

Chlamydia-vaksine

Info

Publication number
NO974561L
NO974561L NO974561A NO974561A NO974561L NO 974561 L NO974561 L NO 974561L NO 974561 A NO974561 A NO 974561A NO 974561 A NO974561 A NO 974561A NO 974561 L NO974561 L NO 974561L
Authority
NO
Norway
Prior art keywords
chlamydia vaccine
chlamydia
vaccine
immunostimulants
mpl
Prior art date
Application number
NO974561A
Other languages
English (en)
Norwegian (no)
Other versions
NO974561D0 (no
Inventor
Jean-Paul Prieels
Moncef Mohamed Slaoui
Jean-Francois Maisonneuve
Vincent Verlant
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of NO974561D0 publication Critical patent/NO974561D0/no
Publication of NO974561L publication Critical patent/NO974561L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/118Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO974561A 1995-04-03 1997-10-02 Chlamydia-vaksine NO974561L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9506863.1A GB9506863D0 (en) 1995-04-03 1995-04-03 Vaccines
PCT/EP1996/001463 WO1996031236A1 (en) 1995-04-03 1996-04-01 Chlamydia vaccines

Publications (2)

Publication Number Publication Date
NO974561D0 NO974561D0 (no) 1997-10-02
NO974561L true NO974561L (no) 1997-11-26

Family

ID=10772426

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974561A NO974561L (no) 1995-04-03 1997-10-02 Chlamydia-vaksine

Country Status (23)

Country Link
EP (1) EP0820304B1 (el)
JP (2) JPH11503142A (el)
KR (1) KR19980703666A (el)
CN (1) CN1185740A (el)
AT (1) ATE193974T1 (el)
AU (1) AU700548B2 (el)
BR (1) BR9604853A (el)
CA (1) CA2215520C (el)
CZ (1) CZ313497A3 (el)
DE (1) DE69608959T2 (el)
DK (1) DK0820304T3 (el)
ES (1) ES2149466T3 (el)
GB (1) GB9506863D0 (el)
GR (1) GR3033764T3 (el)
HK (1) HK1008495A1 (el)
HU (1) HUP9801572A3 (el)
NO (1) NO974561L (el)
NZ (1) NZ306443A (el)
PL (1) PL322620A1 (el)
PT (1) PT820304E (el)
TR (1) TR199701113T1 (el)
WO (1) WO1996031236A1 (el)
ZA (1) ZA962616B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
US20010048927A1 (en) 2000-02-01 2001-12-06 Richard Stephens Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia
US7105171B2 (en) 2002-03-07 2006-09-12 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
BRPI0609547A2 (pt) * 2005-03-31 2011-10-18 Glaxosmithkline Biolog Sa composição, uso de uma composição, método para o tratamento ou prevenção de infecção por chlamydia, uso de uma ou mais proteìnas de chlamydia, de fragmentos imunogênicos das mesmas ou de polinucleotìdeos codificando os mesmos, método para o tratamento ou prevenção de infecção por chlamydia, e, método para a determinação prévia de infecção por chlamydia em um indivìduo
US8541007B2 (en) 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
EP2576602B1 (en) 2010-05-28 2020-02-12 Spixia Biotechnology AB Chimeric momp antigen, method and use
CN113940994B (zh) * 2021-11-09 2023-09-15 南华大学 壳聚糖-Pickering乳液白细胞介素12佐剂体系的制备方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9000207A (el) * 1990-01-29 1991-08-16 Duphar Int Res
JP3183665B2 (ja) * 1990-12-10 2001-07-09 エントルメド インコーポレーテッド コレステロール過剰血症およびアテローム性動脈硬化を防止するためのコレステロールに体するワクチン
CH682455A5 (fr) * 1991-07-25 1993-09-30 Serge Liotet Composition vaccinale.
JPH05339169A (ja) * 1992-03-03 1993-12-21 Dai Ichi Seiyaku Co Ltd 経口ワクチン
ES2108278T3 (es) * 1992-06-25 1997-12-16 Smithkline Beecham Biolog Composicion de vacuna con coadyuvantes.

Also Published As

Publication number Publication date
PT820304E (pt) 2000-11-30
KR19980703666A (ko) 1998-12-05
EP0820304B1 (en) 2000-06-21
CA2215520A1 (en) 1996-10-10
TR199701113T1 (xx) 1998-03-21
AU5499996A (en) 1996-10-23
GB9506863D0 (en) 1995-05-24
AU700548B2 (en) 1999-01-07
HK1008495A1 (en) 1999-05-14
DE69608959D1 (de) 2000-07-27
JPH11503142A (ja) 1999-03-23
ZA962616B (en) 1996-11-27
CA2215520C (en) 2008-01-22
BR9604853A (pt) 1998-06-16
HUP9801572A3 (en) 1999-04-28
DK0820304T3 (da) 2000-08-28
HUP9801572A2 (hu) 1998-10-28
MX9707638A (es) 1998-06-28
ES2149466T3 (es) 2000-11-01
WO1996031236A1 (en) 1996-10-10
DE69608959T2 (de) 2000-11-16
CZ313497A3 (cs) 1998-03-18
PL322620A1 (en) 1998-02-02
CN1185740A (zh) 1998-06-24
ATE193974T1 (de) 2000-07-15
EP0820304A1 (en) 1998-01-28
GR3033764T3 (en) 2000-10-31
NZ306443A (en) 1999-02-25
NO974561D0 (no) 1997-10-02
JP2007308508A (ja) 2007-11-29

Similar Documents

Publication Publication Date Title
DK0865297T3 (da) Vaccinesammensætninger til intranasal administration omfattende chitosan og anvendelsen deraf
DK0729951T3 (da) Naphthylforbindelser, mellemprodukter, præparater og fremgangsmåder
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
HUP9900935A2 (hu) Baktériumellenes és gombaellenes hatású peptid és eljárás az előállítására
NO974561L (no) Chlamydia-vaksine
DK0871656T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
NO960775L (no) Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
WO2002035981A3 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
SE9600120D0 (sv) Novel medical use
DK0863991T3 (da) Antigeniske præparater
TR199600932T1 (tr) Yeni peptidlerin bagisiklik düzenleyici (immünomodülatör)etkileri.
BR0016941A (pt) Derivados de aminometil-fenil-ciclohexanona
EE03514B1 (et) Ühendite kombinatsioon HIV infektsiooni või AIDS-i raviks, selle kasutamine ja farmatseutiline kompositsioon
NO970185L (no) Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi
DK0728741T3 (da) Substituerede benzensulfonylurinstoffer og -thiourinstoffer, fremgangsmåde til fremstilling deraf, anvendelse deraf til fre
AU5520796A (en) Peptide-based vaccine against papillomavirus infection
KR970001319A (ko) 일시적으로 불활성화된 벤조일 퍼옥사이드, 이의 제조방법 및 이의 용도
DK0842135T3 (da) Fremgangsmåde til fremstilling alpha, omega-bromchloralkaner
NO975487L (no) 2-azabicyklo£2,2,1|heptanderivater, deres fremstilling og anvendelse
KR970041153U (ko) 피스톤의 카본 제거기
IT1281069B1 (it) Preparazione di metossimetilmelammine.
KR970041220U (ko) 압축링